The heterogeneity of asymmetric tau distribution is associated with an early age at onset and poor prognosis in Alzheimer’s disease

The heterogeneity of asymmetric tau distribution is associated with an early age at onset and poor prognosis in Alzheimer’s disease

Purpose: Left-right asymmetry, an important feature of brain development, has been implicated in neurodegenerative diseases, although it’s less discussed in typical Alzheimer’s disease (AD). We sought to investigate whether asymmetric tau deposition plays a potential role in AD heterogeneity. Method...

Full description

Bibliographic Details
Main Authors:	Jiaying Lu, Zhengwei Zhang, Ping Wu, Xiaoniu Liang, Huiwei Zhang, Jimin Hong, Christoph Clement, Tzu-Chen Yen, Saineng Ding, Min Wang, Zhenxu Xiao, Axel Rominger, Kuangyu Shi, Yihui Guan, Chuantao Zuo, Qianhua Zhao
Format:	Article
Language:	English
Published:	Elsevier 2023-01-01
Series:	NeuroImage: Clinical
Subjects:	Asymmetry Tau Positron emission tomography Alzheimer’s disease Age Prognosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213158223001055

Similar Items

Detection of individual brain tau deposition in Alzheimer's disease based on latent feature-enhanced generative adversarial network
by: Jiehui Jiang, et al.
Published: (2024-05-01)

Uncovering distinct progression patterns of tau deposition in progressive supranuclear palsy using [18F]Florzolotau PET imaging and subtype/stage inference algorithmResearch in context
by: Jimin Hong, et al.
Published: (2023-11-01)

Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms
by: Chul Hyoung Lyoo, et al.
Published: (2018-01-01)

Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimagingResearch in context
by: Stephanie Doering, et al.
Published: (2024-05-01)

Brain Network and Abnormal Hemispheric Asymmetry Analyses to Explore the Marginal Differences in Glucose Metabolic Distributions Among Alzheimer's Disease, Parkinson's Disease Dementia, and Lewy Body Dementia
by: Danyan Chen, et al.
Published: (2019-04-01)

Optimization and Biodistribution of [11C]-TKF, An Analog of Tau Protein Imaging Agent [18F]-THK523
by: Yanyan Kong, et al.
Published: (2016-08-01)

18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
by: Niklas Mattsson, et al.
Published: (2017-09-01)

Parametric Estimation of Reference Signal Intensity for Semi-Quantification of Tau Deposition: A Flortaucipir and [18F]-APN-1607 Study
by: Huiwei Zhang, et al.
Published: (2021-06-01)

Tau Filaments and the Development of Positron Emission Tomography Tracers
by: Michel Goedert, et al.
Published: (2018-02-01)

Characteristics of Tau and Its Ligands in PET Imaging
by: Ryuichi Harada, et al.
Published: (2016-01-01)

Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer’s disease
by: Hanna Cho, et al.
Published: (2020-09-01)

Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology
by: Adam Martersteck, et al.
Published: (2022-08-01)

The impact of kidney function on plasma neurofilament light and phospho-tau 181 in a community-based cohort: the Shanghai Aging Study
by: Jie Wu, et al.
Published: (2024-02-01)

Untangling tau imaging
by: Victor L. Villemagne, et al.
Published: (2016-01-01)

Findings of 18F‐PI‐2620 tau PET imaging in patients with Alzheimer’s disease and healthy controls in relation to the plasma P‐tau181 levels in a Japanese sample
by: Shogyoku Bun, et al.
Published: (2022-12-01)

What’s the cut-point?: a systematic investigation of tau PET thresholding methods
by: Alexandra J. Weigand, et al.
Published: (2022-04-01)

Tau and atrophy: domain-specific relationships with cognition
by: Leonardino A. Digma, et al.
Published: (2019-07-01)

The Sensitivity of Tau Tracers for the Discrimination of Alzheimer’s Disease Patients and Healthy Controls by PET
by: Zohreh Mohammadi, et al.
Published: (2023-02-01)

Cross‐sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology
by: Brian A. Gordon, et al.
Published: (2018-01-01)

In vivo coupling of tau pathology and cortical thinning in Alzheimer's disease
by: Elijah Mak, et al.
Published: (2018-01-01)

Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease
by: Wha Jin Lee, et al.
Published: (2022-09-01)

Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease
by: Min Seok Baek, et al.
Published: (2020-10-01)

Interaction of APOE4 alleles and PET tau imaging in former contact sport athletes
by: Anna Vasilevskaya, et al.
Published: (2020-01-01)

Association of Odor Identification Ability With Amyloid-β and Tau Burden: A Systematic Review and Meta-Analysis
by: Lihui Tu, et al.
Published: (2020-11-01)

Based on Tau PET Radiomics Analysis for the Classification of Alzheimer’s Disease and Mild Cognitive Impairment
by: Fangyang Jiao, et al.
Published: (2023-02-01)

Plasma tau complements CSF tau and P‐tau in the diagnosis of Alzheimer's disease
by: Silvia Fossati, et al.
Published: (2019-12-01)

The Fate of Tau Aggregates Between Clearance and Transmission
by: Assel Seitkazina, et al.
Published: (2022-07-01)

Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease
by: Anne Maass, et al.
Published: (2017-08-01)

Prediction of rapid amyloid and phosphorylated‐Tau accumulation in cognitively healthy individuals
by: Ivan Koychev, et al.
Published: (2020-01-01)

Editorial: Tau Protein: Mechanisms From Health to Degeneration
by: Isabel Lastres-Becker, et al.
Published: (2021-11-01)

Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease
by: Zhenxu Xiao, et al.
Published: (2021-07-01)

Synergistic interaction of high blood pressure and cerebral beta-amyloid on tau pathology
by: Taewon Kim, et al.
Published: (2022-12-01)

Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies
by: Cinzia Maschio, et al.
Published: (2022-04-01)

Development, initial validation, and application of a visual read method for [18F]MK‐6240 tau PET
by: Joanna L. Shuping, et al.
Published: (2023-01-01)

Asymmetric amyloid deposition in preclinical Alzheimer’s disease: A PET study
by: Pernille L. Kjeldsen, et al.
Published: (2022-01-01)

Longitudinal predictive modeling of tau progression along the structural connectome
by: Fan Yang, et al.
Published: (2021-08-01)

Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
by: Seun Jeon, et al.
Published: (2019-08-01)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
by: Nicholas J. Ashton, et al.
Published: (2022-02-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-06-01)

Reduced SV2A and GABAA receptor levels in the brains of type 2 diabetic rats revealed by [18F]SDM-8 and [18F]flumazenil PET
by: Yanyan Kong, et al.
Published: (2024-03-01)